Document is current
Any future updates will be listed below
-
Authors
Walsh, Elaine M. https://orcid.org/0000-0002-9950-5978
Gucalp, Ayca
Patil, Sujata
Edelweiss, Marcia
Ross, Dara S.
Razavi, Pedram
Modi, Shanu
Iyengar, Neil M.
Sanford, Rachel
Troso-Sandoval, Tiffany
Gorsky, Mila
Bromberg, Jacqueline
Drullinsky, Pamela
Lake, Diana
Wong, Serena
DeFusco, Patricia Ann
Lamparella, Nicholas
Gupta, Ranja
Tabassum, Tasmila
Boyle, Leigh Ann
Arumov, Artavazd
Traina, Tiffany A.
-
Funding
Funding for this research was provided by:
National Institutes of Health (P30 CA008748)
Astellas Pharma US
Pfizer
- License Information
-
More Information
Article History
Received: 18 April 2022
Accepted: 29 June 2022
First Online: 20 August 2022
Declarations
:
: A.G. reports research funding from Pfizer, Innocrin Pharma, Merck, Novartis, Roche, Oncotherapy, BioAtla, Zenith Epigenetics, and Bristol-Myers Squibb paid to the institution. P.R. reports receiving institutional grant/funding from Grail/Illumina, Novartis, AstraZeneca, Epic Sciences, Invitae/ArcherDx, Tempus, Inivata, Biothernostics; Consultation/Ad board/Honoraria from Novartis, Foundation Medicine, AstraZeneca, Pfizer, Daiichi, Epic Sciences, Inivata, Natera, Biovica, and Tempus. S.M. reports speaking/honoraria and research funds from Astrazeneca, Daiichi Sankyo, Seagen, Genetech, and Macrogenics. N.M.I. reports research grants (to institution) from National Cancer Society, American Cancer Society, Breast Cancer Research Foundation, and Novartis; consulting fees from Novartis and Seattle Genetics. E.M.W., S.P., M.E., D.S.R., R.S., T. T-S., M.G., J.B., P.D., D.L., S.W., P.A.D., N.L., R.G., T.T., L.A.B., A.A., and T.A.T. declare they have no financial interests.
